1. Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm. 2006;71(suppl):53-65. [PubMed]

2. Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy. 2007;27(12, pt 2):174S-185S. [PubMed]

3. Fowler CJ, Wiberg A, Oreland L, et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm. 1980;49:1-20. [PubMed]

4. Fernandez HH, Chen JJ. Monoamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol. 2007;30:150-168. [PubMed]

5. Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet. 2004;363: 1783-1793. [PubMed]

6. Riederer P, Youdim MBH, Rausch WD, et al. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978;43:217-226. [PubMed]

7. Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy. 2007;27(12, pt 2):161S-173S. [PubMed]

8. Youdim MB, Gross A, Finberg JP. Rasagiline (N-propargyl-IR(+)-aminoindan): a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506. [PubMed]

9. Eldepryl [package insert]. Tampa, FL: Somerset Pharmaceuticals, Inc; 1997.

10. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58:11-17. [PubMed]

11. Movement Disorders Society. Management of Parkinson’s disease: an evidence- based review. Mov Disord. 2002;17(suppl 4):S1-S166. [PubMed]

12. Palhagen S, Heinonen E, Hagghurd J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200-1206. [PubMed]

13. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-995. [PubMed]

14. Haberle D, Szoko E, Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem. 2002;9:47-51. [PubMed]

15. Shin H-S. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997;25:657-662. [PubMed]

16. Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432. [PubMed]

17. Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptoms. Clin Neuropharmacol. 2007;30:295-300. [PubMed]

18. Azilect [package insert]. Kansas City, MO: Teva Neuroscience, Inc; 2006.

19. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: the TEMPO study. Arch Neurol. 2002;59:1937-1943. [PubMed]

20. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease. Arch Neurol. 2004;61:561-566. [PubMed]

21. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov Disord. 2009;24:564-573. [PubMed]

22. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23:2194-2201. [PubMed]

23. Olanow CW, Rascol O. The ADAGIO study: secondary and additional endpoints. Neurology. 2009;72(suppl 3):A412. Presented at the 61st Annual Meeting of the American Academy of Neurology, Seattle, Washington, April 25-May 2, 2009.

24. Olanow CW, Rascol O. Early rasagiline slows UPDRS decline in the ADAGIO delayed start study. Ann Neurol. 2008;64(suppl 12):S68. Presented at the 133rd Annual Meeting of the American Neurological Association, Salt Lake City, Utah, September 21-24, 2008.

25. Lewitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology. 2009;72:1352-1357. [PubMed]

26. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954. [PubMed]

27. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7, suppl 2):S18-S23. [PubMed]

28. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746-748. [PubMed]

29. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(7, suppl 2):S24-S29. [PubMed]

30. deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716-1721. [PubMed]

31. Emsam [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2008.

32. Goren T, Sasson N. A clinical pharmacology study to determine the selective and non-selective doses of the monoamine oxidase type B (MOA-B) inhibitor, rasagiline. Mov Disord. 2009;24(suppl 1):S264. Presented at the 13th International Congress of Parkinson’s Disease and Movement Disorders, Paris, France, June 7-11, 2009.

33. Heinonen ES, Myllal VV. Safety of selegiline (Deprenyl) in the treatment of Parkinson’s disease. Drug Saf. 1998;19:11-22. [PubMed]

34. Wilkinson J, Reichwein S, Stern M. Safety and tolerability of tyramine challenge in levodopa-treated Parkinson’s disease (PD) patients receiving rasagiline. Neurology. 2008;70(suppl 1):A58-A59 Presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago, Illinois, April 12-19, 2008.